Literature DB >> 20011570

Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer.

Sabine Tejpar1, Robert D Odze.   

Abstract

OverviewPredictive/Prognostic FactorsKRAS StatusLigands of EGFRPhosphoinositide 3-kinases (PI3Ks)Phosphatase and Tensin Homolog (PTEN)Microsatellite Instability (MSI)Inflammatory Bowel Disease (IBD) and Colon CancerFlat and Polypoid DysplasiaOther Non-Morphology-Based Predictive Markers of Cancer in IBDPotential Applications in Clinical PracticeTargeting TherapyFuture Directions.

Entities:  

Year:  2009        PMID： 20011570      PMCID： PMC2791383     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  49 in total

1.  Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia.

Authors:  N A Wong; N J Mayer; S MacKell; H M Gilmour; D J Harrison
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

2.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

3.  Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia.

Authors:  R F Willenbucher; D E Aust; C G Chang; S J Zelman; L D Ferrell; D H Moore; F M Waldman
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 4.  Pathology of dysplasia and cancer in inflammatory bowel disease.

Authors:  Robert D Odze
Journal:  Gastroenterol Clin North Am       Date:  2006-09       Impact factor: 3.806

5.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

Authors:  Matthew D Rutter; Brian P Saunders; Kay H Wilkinson; Steve Rumbles; Gillian Schofield; Michael A Kamm; Christopher B Williams; Ashley B Price; Ian C Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

7.  Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.

Authors:  W R Connell; J E Lennard-Jones; C B Williams; I C Talbot; A B Price; K H Wilkinson
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

8.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

9.  PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Authors:  Hans Prenen; Jef De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

10.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Authors:  F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640
View more
  2 in total

Review 1.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

2.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.